Tekmira Pharmaceuticals TKMR shares are trading seven percent higher Monday after Leerink revealed a $25 price target and Outperform rating.
The company has significant opportunity beyond Ebola with its RNAi product and pipeline, according to the research report. These factors make Tekmira “uniquely positioned.”
TKM-HBV, Tekmira’s hepatitis B drug has the potential to be a major growth catalyst says analyst Michael Schmidt. An investigational new drug application is expected to be filed in the second half of 2015.
Related Link: Deutsche Bank Raises Achillion Price Target 138%
Tekmira shares are up 106 percent over the past month; the company is one of few names mentioned in the recent Ebola outbreak. Shares fell 50 percent from peak to trough last week, but today’s rally is fueling a recovery.
The issue was last trading hands at $19.30, a 6.75 percent gain.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.